These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 9593165)

  • 21. In vitro activity of sparfloxacin, ciprofloxacin, ofloxacin, and other antibiotics against bloodstream isolates of gram-positive cocci.
    Rotstein C; Amsterdam D; Beam TR; Mandell LA; Gorzynski EA
    Diagn Microbiol Infect Dis; 1993 Jul; 17(1):85-91. PubMed ID: 8395375
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparative in vitro activity of Meropenem, Imipenem and Piperacillin/tazobactam against 1071 clinical isolates using 2 different methods: a French multicentre study.
    Joly-Guillou ML; Kempf M; Cavallo JD; Chomarat M; Dubreuil L; Maugein J; Muller-Serieys C; Roussel-Delvallez M
    BMC Infect Dis; 2010 Mar; 10():72. PubMed ID: 20298555
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The in-vitro activity of piperacillin/tazobactam, ciprofloxacin, ceftazidime and imipenem against multiple resistant gram-negative bacteria.
    Mehtar S; Drabu YJ; Blakemore PH
    J Antimicrob Chemother; 1990 Jun; 25(6):915-9. PubMed ID: 2164513
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Argentinean collaborative multicenter study on the in vitro comparative activity of piperacillin-tazobactam against selected bacterial isolates recovered from hospitalized patients.
    Casellas JM; Tomé G; Bantar C; Bertolini P; Blázquez N; Borda N; Couto E; Cudmani N; Guerrera J; Juárez MJ; López T; Littvik A; Méndez E; Notario R; Ponce G; Quinteros M; Salamone F; Sparo M; Sutich E; Vaylet S; Wolff L
    Diagn Microbiol Infect Dis; 2003 Nov; 47(3):527-37. PubMed ID: 14596972
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mechanism of action of sparfloxacin against and mechanism of resistance in gram-negative and gram-positive bacteria.
    Piddock LJ; Zhu M
    Antimicrob Agents Chemother; 1991 Nov; 35(11):2423-7. PubMed ID: 1666499
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In vitro activity of sparfloxacin and six reference antibiotics against gram-positive bacteria.
    Louie A; Baltch AL; Ritz WJ; Smith RP
    Chemotherapy; 1991; 37(4):275-82. PubMed ID: 1665123
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparative in vitro activity of gatifloxacin, grepafloxacin, levofloxacin, moxifloxacin and trovafloxacin against 4151 Gram-negative and Gram-positive organisms.
    Blondeau JM; Laskowski R; Bjarnason J; Stewart C
    Int J Antimicrob Agents; 2000 Feb; 14(1):45-50. PubMed ID: 10717500
    [TBL] [Abstract][Full Text] [Related]  

  • 28. In vitro activities of three nonfluorinated quinolones against representative bacterial isolates.
    Barry AL; Fuchs PC; Brown SD
    Antimicrob Agents Chemother; 2001 Jun; 45(6):1923-7. PubMed ID: 11353655
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In vitro antibacterial activity of the new quinolone Bay y3118 against clinical isolates.
    Ravizzola G; Pizzi R; Pirali F; Turano A
    J Chemother; 1994 Dec; 6(6):392-8. PubMed ID: 7699426
    [TBL] [Abstract][Full Text] [Related]  

  • 30. In vitro activities of quinolones, beta-lactams, tobramycin, and trimethoprim-sulfamethoxazole against nonfermentative gram-negative bacilli.
    Fass RJ; Barnishan J; Solomon MC; Ayers LW
    Antimicrob Agents Chemother; 1996 Jun; 40(6):1412-8. PubMed ID: 8726011
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [In vitro activity of prulifloxacin, levofloxacin and ciprofloxacin against urinary pathogens].
    Noviello S; Ianniello F; Leone S; Esposito S
    Infez Med; 2006 Mar; 14(1):24-8. PubMed ID: 17405239
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bacterial eradication by clinafloxacin, CI-990, and ciprofloxacin employing MBC test, in-vitro time-kill and in-vivo time-kill studies.
    Cohen MA; Huband MD; Yoder SL; Gage JW; Roland GE
    J Antimicrob Chemother; 1998 Jun; 41(6):605-14. PubMed ID: 9687098
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of in vitro activity of trovafloxacin against gram-positive and gram-negative organisms with quinolones and beta-lactam antimicrobial agents.
    Dembry LM; Roberts JC; Schock KD; Marino SP; Farrel PA; Andriole VT
    Diagn Microbiol Infect Dis; 1998 May; 31(1):301-11. PubMed ID: 9597391
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Activity of CP 99,219 (trovafloxacin) compared with ciprofloxacin, sparfloxacin, clinafloxacin, lomefloxacin and cefuroxime against ten penicillin-susceptible and penicillin-resistant pneumococci by time-kill methodology.
    Visalli MA; Jacobs MR; Appelbaum PC
    J Antimicrob Chemother; 1996 Jan; 37(1):77-84. PubMed ID: 8647777
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In vitro activity of BAY 12-8039, a new fluoroquinolone.
    Woodcock JM; Andrews JM; Boswell FJ; Brenwald NP; Wise R
    Antimicrob Agents Chemother; 1997 Jan; 41(1):101-6. PubMed ID: 8980763
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Activity of newer fluoroquinolones against gram-positive and gram-negative bacteria isolated from ocular infections: an in vitro comparison.
    Duggirala A; Joseph J; Sharma S; Nutheti R; Garg P; Das T
    Indian J Ophthalmol; 2007; 55(1):15-9. PubMed ID: 17189881
    [TBL] [Abstract][Full Text] [Related]  

  • 37. In vitro activity of sparfloxacin compared with ciprofloxacin and ofloxacin against respiratory tract pathogens.
    Malmborg AS; Ahlén S
    Chemotherapy; 1993; 39(1):32-5. PubMed ID: 8383030
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparisons of parenteral broad-spectrum cephalosporins tested against bacterial isolates from pediatric patients: report from the SENTRY Antimicrobial Surveillance Program (1998-2004).
    Jones RN; Sader HS; Fritsche TR; Pottumarthy S
    Diagn Microbiol Infect Dis; 2007 Jan; 57(1):109-16. PubMed ID: 16930923
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Nemonoxacin has potent activity against gram-positive, but not gram-negative clinical isolates.
    Li ZX; Liu YN; Wang R; Li AM
    Clin Ter; 2015; 166(6):e374-80. PubMed ID: 26794819
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cross-susceptibility of cefpirome and four other beta-lactams against isolates from haematology/oncology and intensive care units. International Study Group.
    Spencer RC
    Scand J Infect Dis Suppl; 1993; 91():25-32. PubMed ID: 8290900
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.